Bactiguard Holding AB (publ) (BACTI_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, operator, and welcome everyone to Bactiguard's presentation of the first quarter of twenty twenty six. Patrick and I will go through the presentation together today. I'll start with an overview of the quarter and our strategic progress, and Patrick will then walk you through our financials in more detail. We will, of course, open up for questions at the end. The title of today's presentation is Building Momentum Through Partnerships, Regulatory Progress, and Organizational Strength, and that reflects how we view this quarter, not driven by a single event, but by continued execution across several areas that are important for Bactiguard's long term development. I'm actually joining you today from The US where the Heart Rhythm Society meeting starts in Chicago later today. And with that, let me start with a high level overview of the quarter. Next slide, please. Starting with the key figures and highlights. From a financial perspective, we delivered continued profitability with adjusted EBITDA of 4,900,000 SEK. Reported revenues were lower compared with the same quarter last year, and we will come back to the underlying drivers behind that as we move through the presentation. Strategically, however, the quarter has been an important one. We saw increased sales of Bactiguard coated products across our collaborations, and BD has initiated sales of the Bactiguard coated Foley in parts of Europe, marking another step in expanding the reach of our technology. This was also the first reported quarter under the updated business setup with Zimmer Biomet that we announced in late December and which has been an important transition point for that partnership. During the quarter, we also continued to invest in regulatory related activities, which are critical for suppo...